Associations of High-Sensitivity Cardiac Troponin and Natriuretic Peptide With Subsequent Risk of Infection in Persons Without Cardiovascular Disease : The Atherosclerosis Risk in Communities Study
© The Author(s) 2019. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
Whether persons without prevalent cardiovascular disease (CVD) but elevated levels of high-sensitivity cardiac troponin T (hs-cTnT) or N-terminal pro-B-type natriuretic peptide (NT-proBNP) are at high risk of infection is unknown. Using 1996-2013 data from the Atherosclerosis Risk in Communities Study, we estimated hazard ratios for incident hospitalization with infection in relation to plasma hs-cTnT and NT-proBNP concentrations among participants without prevalent CVD and contrasted them with hazard ratios for persons with prevalent CVD (coronary heart disease, heart failure, or stroke). In a multivariable Cox model, prevalent CVD was significantly associated with risk of hospitalization with infection (hazard ratio (HR) = 1.31, 95% confidence interval (CI): 1.19, 1.45). Among participants without prevalent CVD, hs-cTnT and NT-proBNP were independently associated with infection risk in a graded fashion (e.g., HR = 1.44 (95% CI: 1.24, 1.69) for hs-cTnT ≥14 ng/L and HR = 1.28 (95% CI: 1.14, 1.44) for hs-cTnT 9-13 ng/L vs. <3 ng/L; HR = 1.57 (95% CI: 1.35, 1.81) for NT-proBNP ≥248.1 pg/mL and HR = 1.19 (95% CI: 1.06, 1.34) for NT-proBNP 137.2-248.0 pg/mL vs. <48.1 pg/mL). The 15-year cumulative incidences of hospitalization with infection were similar for participants with prevalent CVD and participants who did not have prevalent CVD but had hs-cTnT ≥14 ng/L or NT-proBNP ≥248.1 pg/mL. Thus, hs-cTnT and NT-proBNP were independently associated with infection risk. Persons without CVD but with elevated hs-cTnT or NT-proBNP levels should be recognized to have similar infection risks as persons with prevalent CVD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:188 |
|---|---|
| Enthalten in: |
American journal of epidemiology - 188(2019), 12 vom: 31. Dez., Seite 2146-2155 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ishigami, Junichi [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 03.04.2020 Date Revised 31.12.2020 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/aje/kwz113 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM296826200 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM296826200 | ||
| 003 | DE-627 | ||
| 005 | 20231225090657.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/aje/kwz113 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0989.xml |
| 035 | |a (DE-627)NLM296826200 | ||
| 035 | |a (NLM)31063194 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ishigami, Junichi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Associations of High-Sensitivity Cardiac Troponin and Natriuretic Peptide With Subsequent Risk of Infection in Persons Without Cardiovascular Disease |b The Atherosclerosis Risk in Communities Study |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.04.2020 | ||
| 500 | |a Date Revised 31.12.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2019. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
| 520 | |a Whether persons without prevalent cardiovascular disease (CVD) but elevated levels of high-sensitivity cardiac troponin T (hs-cTnT) or N-terminal pro-B-type natriuretic peptide (NT-proBNP) are at high risk of infection is unknown. Using 1996-2013 data from the Atherosclerosis Risk in Communities Study, we estimated hazard ratios for incident hospitalization with infection in relation to plasma hs-cTnT and NT-proBNP concentrations among participants without prevalent CVD and contrasted them with hazard ratios for persons with prevalent CVD (coronary heart disease, heart failure, or stroke). In a multivariable Cox model, prevalent CVD was significantly associated with risk of hospitalization with infection (hazard ratio (HR) = 1.31, 95% confidence interval (CI): 1.19, 1.45). Among participants without prevalent CVD, hs-cTnT and NT-proBNP were independently associated with infection risk in a graded fashion (e.g., HR = 1.44 (95% CI: 1.24, 1.69) for hs-cTnT ≥14 ng/L and HR = 1.28 (95% CI: 1.14, 1.44) for hs-cTnT 9-13 ng/L vs. <3 ng/L; HR = 1.57 (95% CI: 1.35, 1.81) for NT-proBNP ≥248.1 pg/mL and HR = 1.19 (95% CI: 1.06, 1.34) for NT-proBNP 137.2-248.0 pg/mL vs. <48.1 pg/mL). The 15-year cumulative incidences of hospitalization with infection were similar for participants with prevalent CVD and participants who did not have prevalent CVD but had hs-cTnT ≥14 ng/L or NT-proBNP ≥248.1 pg/mL. Thus, hs-cTnT and NT-proBNP were independently associated with infection risk. Persons without CVD but with elevated hs-cTnT or NT-proBNP levels should be recognized to have similar infection risks as persons with prevalent CVD | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a N-terminal pro-B-type natriuretic peptide | |
| 650 | 4 | |a cardiovascular disease | |
| 650 | 4 | |a high-sensitivity cardiac troponin T | |
| 650 | 4 | |a hospitalization | |
| 650 | 4 | |a infection | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Peptide Fragments |2 NLM | |
| 650 | 7 | |a TNNT2 protein, human |2 NLM | |
| 650 | 7 | |a Troponin T |2 NLM | |
| 650 | 7 | |a pro-brain natriuretic peptide (1-76) |2 NLM | |
| 650 | 7 | |a Natriuretic Peptide, Brain |2 NLM | |
| 650 | 7 | |a 114471-18-0 |2 NLM | |
| 700 | 1 | |a Hoogeveen, Ron C |e verfasserin |4 aut | |
| 700 | 1 | |a Ballantyne, Christie M |e verfasserin |4 aut | |
| 700 | 1 | |a Folsom, Aaron R |e verfasserin |4 aut | |
| 700 | 1 | |a Coresh, Josef |e verfasserin |4 aut | |
| 700 | 1 | |a Selvin, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Matsushita, Kunihiro |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of epidemiology |d 1965 |g 188(2019), 12 vom: 31. Dez., Seite 2146-2155 |w (DE-627)NLM000012327 |x 1476-6256 |7 nnns |
| 773 | 1 | 8 | |g volume:188 |g year:2019 |g number:12 |g day:31 |g month:12 |g pages:2146-2155 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/aje/kwz113 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 188 |j 2019 |e 12 |b 31 |c 12 |h 2146-2155 | ||